MBCproject_0253_T1_RNA
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_EARLY+0.480
- ESTROGEN_RESPONSE_LATE+0.470
- APICAL_SURFACE+0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.410
- ANGIOGENESIS+0.310
- COAGULATION+0.280
- HYPOXIA+0.250
- PANCREAS_BETA_CELLS+0.240
- XENOBIOTIC_METABOLISM+0.240
- CHOLESTEROL_HOMEOSTASIS+0.230
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.170
- MITOTIC_SPINDLE-0.170
- PROTEIN_SECRETION-0.160
- TGF_BETA_SIGNALING-0.130
- UV_RESPONSE_DN-0.120
- IL6_JAK_STAT3_SIGNALING-0.100
- COMPLEMENT-0.090
- G2M_CHECKPOINT-0.080
- UNFOLDED_PROTEIN_RESPONSE-0.080
- PI3K_AKT_MTOR_SIGNALING-0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_1151_T1_RNA | — | B | 0.764 |
| 2 | R111 | — | — | 0.761 |
| 3 | s0112232 | — | — | 0.748 |
| 4 | TCGA-E9-A6HE-01A-11R-A31O-07 | — | B | 0.746 |
| 5 | MBCProject_0988_T1_RNA | — | B | 0.728 |
| 6 | SAMN03290893 | — | — | 0.727 |
| 7 | MNG610 | — | — | 0.721 |
| 8 | SRR5088877 | — | — | 0.718 |
| 9 | TCGA-BH-A0B4-01A-11R-A00Z-07 | — | C | 0.708 |
| 10 | SRR12696750 | — | — | 0.702 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_EARLY | 0.480 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.470 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.410 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.310 | Remibrutinib | — uncovered |
| COAGULATION | 0.280 | Binimetinib | — uncovered |
| HYPOXIA | 0.250 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.240 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.210 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.210 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.180 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.160 | Idelalisib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.140 | Inavolisib | — uncovered |